Moderna Inc. (MRNA) News
Filter MRNA News Items
MRNA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MRNA News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest MRNA News From Around the Web
Below are the latest news stories about MODERNA INC that investors may wish to consider to help them evaluate MRNA as an investment opportunity.
The Score: Meta Platforms, Moderna, Edison International and More Stocks That Defined the WeekMeta Platforms is ending fact-checking and speech restrictions across Facebook and Instagram, as Chief Executive Mark Zuckerberg embraces a second Trump presidency. Starting in the U.S., Meta will be replacing fact-checkers with a so-called Community Notes system. Zuckerberg built up Facebook’s content-policing efforts in the wake of Trump’s first presidential election. |
Jim Cramer on Moderna, Inc. (MRNA): ‘The Numbers Here Are Staggering, Staggeringly Bad’We recently compiled a list of the 10 S&P 500 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other S&P 500 stocks. Jim Cramer, host of Mad Money, recently discussed the current state of the market and also discussed both the […] |
AI, vaccine distrust, & the future of healthcare: Novartis CEOCan science prevail against this more turbulent backdrop of the Trump administration? Yahoo Finance executive editor Brian Sozzi talks at length with Novartis (NVS) CEO Vas Narasimhan. Narasimhan has led the drug giant since 2018, doing deals that have expanded the company’s pipeline in areas like heart disease and cancer. Still, Narasimhan is feeling pressure to bring the investments to the bottom line to jumpstart its stock price. In the last year, Novartis shares have declined 6.69%. During that same timespan, the S&P 500 and Dow Jones Industrial Average have gained 22.8% and 12%, respectively. The iShares U.S. Healthcare ETF (IYH) is up slightly in the past year. The stock prices of Pfizer (PFE) and Moderna (MRNA) are down 8.5% and 61%, respectively in the past year. For full episo... |
Moderna Gambling on China as Other U.S. Companies Pull BackThe biotech’s efforts to bring its vaccines to the country mean navigating political pushback in the U.S. and the risk of intellectual-property theft in China. |
These Stocks Moved the Most Today: Nvidia, AMD, Palantir, IonQ, Moderna, Vir, Edison International, Constellation Energy, and MoreNvidia shares are flat after falling sharply in the previous session, Palantir stock extends declines, and quantum-computing stocks sink following comments from Nvidia’s CEO. |
Moderna stock forfeits gains as first US bird flu death puts vaccine development in focusThe first human bird flu death in the US has Moderna's vaccine development in focus for investors this week. |
Why Moderna Inc. (MRNA) Is SkyrocketingWe recently published a list of 10 Firms Post Strong Gains Amid Wall Street Bloodbath. In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against other firms post strong gains amid Wall Street bloodbath. Wall Street’s main indices closed sharply in the red on Tuesday, as investors shifted […] |
"Motley Fool Money" 2025 Stock Market PreviewNew year, new market? Motley Fool analysts preview what's in store for investors in 2025, the companies they're excited to watch and the businesses they're worried about. |
There’s a ‘Shadow’ Over Biotech Stocks. Why It Isn‘t All Bad News.Pharmaceutical and biotech stocks may find it tough to outperform the market in the months ahead. Nonspecialist investors have shifted their focus to other sectors, such as tech, following the outcome of the election and uncertainty about what it will mean for the industry, they said. “We believe President-elect Trump will be capable of enacting significant change, and the unpredictability is expected to cast a shadow over the space,” analysts led by Trung Huynh said in their 2025 outlook on the sector. |
Moderna Stock Skyrockets 21% as H5N1 Flu Death Sparks Vaccine Hopes and Investor FrenzyModerna rallies as H5N1 avian flu spreads, boosting interest in its mRNA vaccine and federal backing |